Melin­ta se­cures $142M BAR­DA deal to tar­get pe­di­atric and 'bio­threat' in­di­ca­tions for an­tibi­otics

Melin­ta Ther­a­peu­tics se­cured a BAR­DA deal worth near­ly $142 mil­lion to make two cur­rent­ly ap­proved an­tibi­otics avail­able for chil­dren.

The deal comes rough­ly three years …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER